Boehringer Ingelheim and Walgreens are seeking out people who are overweight, living with obesity or have type 2 diabetes — specifically Black and Hispanic patient populations.
Eli Lilly’s GLP-1 drug achieves endpoints in Phase 3 sleep apnea trials
The sleep apnea results point to the continued clinical promise of GLP-1 drugs for treating other medical conditions and disease states beyond type 2 diabetes and obesity.
After Phase 3 readout, Ionis set on launching FCS agent this year
VX-548, designed as an alternative to opioids in treating acute pain, posted mixed trial results. Some analysts are questioning the commercial viability of Vertex’s drug.
Sagimet’s liver drug impresses in year-long NASH trial
The pill from Sagimet Biosciences led to a statistically significant treatment effect in patients with NASH and moderate-to-severe liver fibrosis at the 52-week mark, data show.
Ionis’ long-term HAE drug lowered attack rates, topline Phase 3 results show
The results from Ionis suggest the drug, donidalorsen, led to a statistically significant reduction in the rate of HAE attacks in patients treated every four or eight weeks.
GSK, the Tigerlily Foundation want to diversify clinical trials